Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) – March 01, 2024

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on February 29, 2024.

Scroll to Top